TNFRSF17 and plasma cell myeloma: In a phase 1 clinical trial for multiple myeloma, anti-BCMA CAR-T cells produced using the PB system also showed positive outcomes and had fewer side effects than other comparable anti-BCMA CAR-T cell products [449].